Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

PROMISE V2 — something new, something old and something borrowed

Prostate-specific membrane antigen-PET has become a valuable diagnostic tool. The second version of the Prostate Cancer Molecular Imaging Standardized Evaluation framework is the next step towards a standardized evaluation and reporting system from primary staging to reassessment of advanced prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Maurer, T., Eiber, M., Schwaiger, M. & Gschwend, J. E. Current use of PSMA-PET in prostate cancer management. Nat. Rev. Urol. 13, 226–235 (2016).

    Article  CAS  PubMed  Google Scholar 

  2. European Association of Urology. EAU, EANM, ESTRO, ESUR, ISUP, SIOG Guidelines on Prostate Cancer. EAU https://uroweb.org/guideline/prostate-cancer (2023).

  3. Chang, S. S. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192–3198 (1999).

    CAS  PubMed  Google Scholar 

  4. Roberts, M. J. et al. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat. Rev. Urol. 20, 23–47 (2023).

    Article  PubMed  Google Scholar 

  5. Fanti, S. et al. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur. J. Nucl. Med. Mol. Imaging 44, 1622–1635 (2017).

    Article  CAS  PubMed  Google Scholar 

  6. Rowe, S. P., Pienta, K. J., Pomper, M. G. & Gorin, M. A. Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0. J. Nucl. Med. 59, 479–485 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Eiber, M. et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J. Nucl. Med. 59, 469–478 (2018).

    Article  PubMed  Google Scholar 

  8. Fanti, S. et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 48, 469–476 (2021).

    Article  PubMed  Google Scholar 

  9. Gafita, A. et al. Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J. Nucl. Med. 63, 1651–1658 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Seifert, R. et al. Second version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur. Urol. 83, 405–412 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel Koehler.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koehler, D. PROMISE V2 — something new, something old and something borrowed. Nat Rev Urol 20, 639–640 (2023). https://doi.org/10.1038/s41585-023-00807-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-023-00807-1

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing